Rima Patel

Rima Patel

Auto-generated profile, based on publicly available information

Rima Patel

Division of Hematology and Oncology, Mount Sinai Tisch Cancer Center, Icahn School of Medicine at Mount Sinai , New York, NY

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in npj Breast Cancer
Verified
Journal Article
Open access
PDF file
RPRima Patel
Rima Patel
PKPaula Klein
Paula Klein
ATAmy Tiersten
Amy Tiersten
JSJoseph A. Sparano
Joseph A. Sparano
Anti-estrogen therapy is a key component of the treatment of both early and advanced-stage hormone receptor (HR)-positive breast cancer. This review discusses the recent emergence of several anti-estrogen therapies, some of which were designed to overcome common mechanisms of endocrine resistance. The new generation of drugs includes selective estrogen receptor modulators (SERMs), orally administered selective estrogen receptor degraders (SERDs), as well as more unique agents such as complete estrogen receptor antagonists (CERANs), proteolysis targeting chimeric (PROTACs), and selective estrogen receptor covalent antagonists (SERCAs). These drugs are at various stages of development and are being evaluated in both early and metastatic settings. We discuss the efficacy, toxicity profile, and completed and ongoing clinical trials for each drug and highlight key differences in their activity and study population that have ultimately influenced their advancement.

10 August 2022 in Cancer
Verified
Journal Article
Closed access
RPRima Patel
Rima Patel
MHMalin Hovstadius
Malin Hovstadius
MKMelanie W. Kier
Melanie W. Kier
EMErin L. Moshier
Erin L. Moshier
BZBrittney S. Zimmerman
Brittney S. Zimmerman
ATAmy Tiersten
Amy Tiersten

13 December 2016 in Case Reports in Infectious Diseases
Verified
Journal Article
Open access
PDF file
RPRima Patel
Rima Patel
VGVedavyas Gannamani
Vedavyas Gannamani
ESEmily Shay
Emily Shay
DADavid Alcid
David Alcid
Extrapulmonary tuberculosis (TB) is uncommon but not rare. Bone and joint involvement constitute about 10% of extrapulmonary TB cases, with the spine being the most frequently affected site. Spinal TB patients typically present with back pain but other constitutional or pulmonary symptoms may be absent, rendering the diagnosis difficult. This case explores challenges in the diagnosis of spinal TB. We report a case of a 39-year-old woman presenting with vague back swelling for many years. Imaging revealed osteomyelitis of the spine but initial studies and cultures were negative for Mycobacterium tuberculosis. The diagnosis was confirmed weeks later when cultures demonstrated Mycobacterium tuberculosis. Considering the severe complications of untreated spinal TB including paraplegia and need for surgical intervention, high suspicion is critical in early diagnosis.

31 December 2024 in Clinical Breast Cancer
Verified
Journal Article
Closed access
RPRima Patel
Rima Patel
CJCao Jin
Cao Jin
DJDiana Jaber
Diana Jaber
NCNicole Casasanta
Nicole Casasanta
MJMayuri Jain
Mayuri Jain
ATAmy Tiersten
Amy Tiersten

10 January 2022 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
RPRima Patel
Rima Patel
ZLZhiqiang Li
Zhiqiang Li
BZBrittney S. Zimmerman
Brittney S. Zimmerman
MFMarc Y. Fink
Marc Y. Fink
JWJason D. Wells
Jason D. Wells
ATAmy Tiersten
Amy Tiersten

18 July 2019 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
PDF file
RPRima Patel
Rima Patel
LPLori Pai
Lori Pai
Introduction: Immune checkpoint inhibitors have transformed the field of oncology moving immuno-oncology to the forefront of cancer treatment. However, immune checkpoint inhibitors can result in serious immune-related adverse events. Hematologic toxicities are rare with incidence of neutropenia from nivolumab less than 1%. Case report: We present a case of refractory neutropenia in a 75-year-old woman with ulcerative colitis on adjuvant nivolumab for stage III melanoma. Management and outcome: The patient's neutropenia did not improve with high-dose intravenous steroids, filgrastim, mycophenolate mofetil, or intravenous immunoglobulin. She also developed significant neurological symptoms from nivolumab. She was transitioned to comfort measures given her persistent symptoms and poor functional status. Discussion: Though hematologic malignancies of immune checkpoint inhibitors are rare, they should be considered after other diagnoses are excluded. We discuss the serious immune-related adverse effects of immune checkpoint inhibitors in a patient with an underlying autoimmune disease and general treatment approaches.